Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-14 · accession 0001209191-23-049810 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-18 | 2023-09-14 | ANAB | Lizzul Paul F. | Chief Medical Off | M - OptEx | — | +6,000 | 8,632 | +228% | — |
| D | 2023-09-18 | 2023-09-14 | ANAB | Lizzul Paul F. | Chief Medical Off | S - Sale+OE | $19.48 | -2,105 | 6,527 | -24% | -$41.0K |
| D | 2023-09-18 | 2023-09-14 | ANAB | Lizzul Paul F. | Chief Medical Off | M - OptEx | $0.00 | -6,000 | 6,000 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-14 | M | A | 6,000 | — | 8,632 | D | — | — | (F1) Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. (F2) Reflects the acquisition of 881 shares acquired under the Company's ESPP. |
| 2 | Common | Common Stock | 2023-09-14 | S | D | 2,105 | $19.48 | 6,527 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-09-14 | M | D | 6,000 | $0.00 | 6,000 | D | — · — to — | 6,000 Common Stock | (F1) Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. (F4) 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |